Phase III Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial of its dengue vaccine candidate TAK-003 data released by manufacturer

The 36-month data showed the vaccine provided 83.6% protection of the need for hospitalisation and 62% overall efficacy against the virus. The protection levels are regardless of an individual’s previous dengue exposure

SPS commentary:

The company is currently seeking approval for TAK-003 in the European Union and in countries where Dengue is endemic and intends to seek approval in the United States later this year.

Biospace Inc.